( (Purpose) ) : To clarify the beneficial blood glucose (BG) level in severely critical ill patients with glucose intolerance. ( (Materials and Methods) ) : Ninety patients were investigated. Their BG control was performed by means of artificial pancreas (AP), STG22. The patients were evaluated at two phases, early phase (E phase about 3 days after admission) and late phase (L phase : about 1 week after E phase) . Based on the daily mean BG level (BGm), patients were classified into 2 groups, i. e., high group (a) and low group (b), which were compared with. Three blood glucose points were selected, on 150, 175, and 200mg/dL (ex. group 150b means the patients with BGm below 150mg/dL) . Parameters studied were included in sex, age, underlying diseases, the amount of administered glucose (G) and insulin (I), rate of septic patients, severity, and mortality. ( (Results) ) : (1) E phase (n=84) ; Group 200b (n=68) had lower glucose, insulin level, and lower mortality (29 vs 56%, p<0.05) as compared to group 200a (n=16) . Other parameters above shown were not significantly different between group 200b and group 200a. (2) L phase (n=88) ; Group 175b (n=58) had lower insulin and lower mortality (28 vs 50%, p<0.05) as compared to group 175a (n=30) . Other parameters were not significantly different between group 175b and group 175a. ( (Interpretation and conclusions) ) : BG control aiming at the BC level lower than 200mg/dL at early stage and that lower than 175mg/dL at about 10 days after admission may link to the improvement of the outcome of the severely critical ill patients from the viewpoint of glucose metabolic state.
View full abstract